Panelists

GEOFFREY VON MALTZAHN

General Partner, Flagship Pioneering

Geoffrey von Maltzahn is an inventor, entrepreneur, CEO, and the co-founder of multiple groundbreaking companies in therapeutics and agriculture that represent, in aggregate, over $9 billion in public and private market capitalization. Through Flagship Labs, Geoffrey founded Generate Biomedicines, Tessera Therapeutics, Indigo Agriculture, Sana Biotechnology, Kaleido Biosciences, Seres Therapeutics, and Axcella Health.

Geoffrey currently serves as CEO and director of Generate Biomedicines and Tessera Therapeutics, chief innovation officer and director of Indigo, and director of Kaleido Biosciences and Sana Biotechnology. He recently served as CEO of Cobalt Biomedicine, which he led from inception to merger with Sana Biotechnology, as well as Kaleido’s CEO, where he led the company from inception to the launch of multiple clinical studies. Geoffrey also previously served as CEO of Indigo, where he led the development of the company’s plant microbiome platform and the discovery of the company’s first commercial products. Previously, Geoffrey was the chief technology officer of Seres Therapeutics, where he led the discovery of SER-109 and built out the company’s discovery platform. 

Geoffrey was awarded a PhD in biomedical engineering and medical physics from MIT under the mentorship of Sangeeta N. Bhatia, MD, PhD; an MS in bioengineering from the University of California, San Diego; and an SB in chemical engineering from MIT.

ENOCH HUANG

VP, Simulation and Modeling Sciences, Pfizer

Enoch S. Huang received an AB in Molecular Biology from Princeton and a PhD in Structural Biology from Stanford. He was a Jane Coffin Childs Fellow at Washington University School of Medicine, where he developed methods for protein structure prediction. After starting his computational biology career at Cereon Genomics, he joined Pfizer’s Cambridge laboratories in 2000. In 2001, he was appointed Head of Molecular Informatics and joined the site leadership team. In 2007 he accepted a global role as Head of Computational Sciences, responsible for developing new computational methods for target selection and compound design. In 2019, Enoch was promoted to Vice President, Simulation and Modelling Sciences, and also charged with leading Integrative Biology for Pfizer Worldwide R&D.

Enoch has also been an Adjunct Assistant Professor of Bioinformatics at Boston University since 2001. He has served on editorial boards for Drug Discovery Today and Chemical Biology & Drug Design, and a variety of advisory boards, like Princeton Biomedical Data Science and the International Society for Computational Biology. Enoch has also served on the program committees at the New York Academy of Sciences, the Massachusetts Biotechnology Council, and on NIH study sections. He has authored over 30 publications and released the Open Source software package PFAAT.

MATTHEW TROTTER

VP Predictive Sciences, BMS

Matthew leads a global team of computational scientists who engage in collaborative research and drive data-driven decisions across the Research & Early Development organization and cross-functional Cell Therapy programs at Bristol Myers Squibb (BMS). His role includes site leadership of the BMS CITRE R&D center in Seville, Spain. Prior to his present role, Matthew joined Celgene as a computational biologist in 2011 and his work since has encompassed target prioritization, elucidation of therapeutic mechanisms, predictive patient selection for clinical programs, and identification of unmet need patient sub-groups in oncology and autoimmune diseases. Strategic contributions at during this period include development of the BMS Informatics & Predictive Sciences department, research governance of internal drug discovery programs and external partnerships, and collaboration with IT groups in the design and delivery of global computational research infrastructure.

 Before his industry career, Matthew obtained a Ph.D. in applied machine learning at University College London (UCL) and performed inter-disciplinary research at both UCL and the University of Cambridge in the UK. His publications cover machine learning, cancer and stem cell biology, bioinformatics, cheminformatics, computational biology, disease stratification and drug discovery.

Moderator